Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Cancer Research

• Publication date

  2012-08-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-11-3260PMID 22912387
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.

  2012cited by this paper
• Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

  2011cited by this paper
• Structure and function of WD40 domain proteins

  2011cited by this paper
• ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

  2011cited by this paper
• Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

  2011cited by this paper
• Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

  2011cited by this paper
• The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

  2011cited by this paper
• Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

  2010cited by this paper
• Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

  2010cited by this paper
• Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling

  2010cited by this paper
• The biology and treatment of EML4-ALK non-small cell lung cancer.

  2010cited by this paper
• PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

  2009influential reference
• KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

  2009cited by this paper
• Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy

  2009cited by this paper
• EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

  2008cited by this paper
• Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

  2008cited by this paper
• A mouse model for EML4-ALK-positive lung cancer

  2008cited by this paper
• Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007influential reference
• Epidermal growth factor receptor mutations in lung cancer

  2007cited by this paper
• Human EML4, a novel member of the EMAP family, is essential for microtubule formation.

  2006cited by this paper
• Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

  2005cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper

• Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer

  2025cites this paper
• Impact of EML4‐ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non‐small Cell Lung Cancer

  2025cites this paper
• EML4-ALK variant-specific genetic interactions shape lung tumorigenesis.

  2025cites this paper
• Inhalable pH-responsive charge-reversal polymer-small interfering RNA polyplexes for directed gene therapy of anaplastic lymphoma kinase fusion-positive lung cancer.

  2025cites this paper
• Severe skin toxicity and early progression following neoadjuvant ensartinib and surgery in anaplastic lymphoma kinase-positive locally advanced lung cancer: a case report

  2025cites this paper
• Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

  2024cites this paper
• ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib

  2024cites this paper
• A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer.

  2024cites this paper
• The mesenchymal morphology of cells expressing the EML4–ALK V3 oncogene is dependent on phosphorylation of Eg5 by NEK7

  2024cites this paper
• Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

  2024cites this paper
• Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

  2024cites this paper
• NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

  2024cites this paper
• Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC

  2024cites this paper
• Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation.

  2024cites this paper
• ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

  2024cites this paper
• Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver

  2024cites this paper
• Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations—a retrospective cohort study

  2023cites this paper
• Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer

  2023cites this paper
• EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries

  2023cites this paper
• ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma.

  2023cites this paper
• Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma Kinase-positive large B-cell lymphoma

  2023cites this paper
• Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?

  2023cites this paper
• Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations.

  2023cites this paper
• ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression

  2023cites this paper
• Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer

  2023cites this paper
• Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.

  2023cites this paper
• Overcoming MET-mediated resistance in oncogene-driven NSCLC

  2023cites this paper
• ALK-positive lung cancer: a moving target

  2023cites this paper
• Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy.

  2022influential citation
• Long-term treatment with ALK inhibitors for postoperative recurrence of ALK-rearranged lung cancer

  2022cites this paper
• EML4-ALK fusion gene in non-small cell lung cancer

  2022cites this paper
• Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence

  2022cites this paper
• Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer

  2022influential citation
• The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine

  2022cites this paper
• ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061).

  2022cites this paper
• Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report

  2022cites this paper
• Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

  2022cites this paper
• Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study.

  2022cites this paper
• A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC

  2022cites this paper
• Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors

  2022cites this paper
• SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report

  2022cites this paper
• Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer

  2022influential citation
• Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report

  2022cites this paper
• Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC

  2022influential citation
• EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity

  2022cites this paper
• Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

  2022cites this paper
• Are all ALK variants created equal? Clinicopathologic features and outcomes: a propensity-matched study

  2021cites this paper
• Targeting EML4-ALK gene fusion variant 3 in thyroid cancer

  2021cites this paper
• Phase‐separated foci of EML4‐ALK facilitate signalling and depend upon an active kinase conformation

  2021cites this paper
• Natural Compounds Targeting Major Signaling Pathways in Lung Cancer

  2021cites this paper
• Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer

  2021cites this paper
• Monitoring therapeutic response and resistance with liquid biopsy

  2021cites this paper
• Clinicopathological features and resistance mechanisms in HIP1‐ALK‐rearranged lung cancer: A multicenter study

  2021cites this paper
• Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged non-small cell lung cancer.

  2021cites this paper
• Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib

  2021cites this paper
• The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis.

  2021cites this paper
• Development of a novel ALK rearrangement screening test for non–small cell lung cancers

  2021cites this paper
• Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells

  2021cites this paper
• OTT_A_319845 4915..4920

  2021cites this paper
• Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

  2021cites this paper
• Molecular Profiles of Brain Metastases: A Focus on Heterogeneity

  2021cites this paper
• Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice

  2021cites this paper
• Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview

  2021cites this paper
• Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report

  2021cites this paper
• Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.

  2021cites this paper
• Identification of novel ALK fusions using DNA / RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients.

  2021cites this paper
• Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in NSCLC

  2021cites this paper
• Next generation sequencing detection in archival surgically resected lung adenocarcinoma specimens harbouring the anaplastic lymphoma kinase fusion protein.

  2020cites this paper
• Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer

  2020cites this paper
• A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.

  2020cites this paper
• A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib

  2020cites this paper
• EBP2, a novel NPM‐ALK‐interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53

  2020cites this paper
• КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ ТАРГЕТНОЙ ТЕРАПИИ В ОТНОШЕНИИ МЕТАСТАТИЧЕСКОГО РАКА ЛЁГКОГО С РАЗЛИЧНЫМИ ТИПАМИ ТРАНСЛОКАЦИЙ ГЕНА ALK

  2020cites this paper
• Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.

  2020cites this paper
• Evolución del tratamiento del cáncer de pulmón no células pequeñas con enfermedad ALK positiva

  2020cites this paper
• Ultrasensitive gene fusion detection reveals fusion variant associated tumor heterogeneity

  2020cites this paper
• Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion

  2020cites this paper
• Detection of non-reciprocal/reciprocal ALK translocation as poor predictive marker in first-line crizotinib-treated ALK-rearranged non-small cell lung cancer patients.

  2020cites this paper
• EML4–ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7

  2020cites this paper
• TRAF1-ALK fusion indicates poor prognosis to ALK tyrosine kinase inhibitors in relapsed/refractory ALK-positive anaplastic large-cell lymphoma patients

  2020cites this paper
• CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS

  2020cites this paper
• Utilidad clínica de la biopsia líquida para el diagnóstico y seguimiento de los pacientes con CPNM y EML4-ALK

  2020cites this paper
• Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients

  2020cites this paper
• Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.

  2020cites this paper
• Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.

  2020cites this paper
• Implementing Companion Diagnostic Testing in the Clinic

  2019cites this paper
• Targeted RNA Sequencing in Non-Small Cell Lung Cancer.

  2019cites this paper
• Defining molecular risk in ALK+ NSCLC

  2019cites this paper
• Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data

  2019cites this paper
• Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non–Small Cell Lung Cancer

  2019cites this paper
• Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinoma

  2019cites this paper
• Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC

  2019cites this paper
• University of Groningen Design, optimization, and multisite evaluation of a targeted next-generation sequencing assay system for RNA fusions and exon-skipping events in non-small cell lung cancer. Blidner,

  2019cites this paper
• The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer

  2019cites this paper
• CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.

  2019cites this paper
• Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine

  2019cites this paper
• Fusion transcripts: Unexploited vulnerabilities in cancer?

  2019cites this paper
• The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis

  2019cites this paper
• Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy.

  2019cites this paper
• Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib

  2019cites this paper